Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine vs S-1 vs Gemcitabine + Nab-paclitaxel in Adjuvant Pancreatic Cancer
NCT03278015Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, tegafur in pancreatic ductal adenocarcinoma (PDAC), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
paclitaxeltegafur
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03278015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278015.